Tonix Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference

Rhea-AI Summary

Tonix Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its CEO, Seth Lederman, M.D., will participate in the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be available on demand for registered participants and can later be accessed on the company's website. Tonix focuses on developing therapies for central nervous system and immunology conditions. Its lead candidate, TNX-102 SL, is in mid-Phase 3 trials for fibromyalgia, while TNX-1800 aims to provide protection against COVID-19.

CHATHAM, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the BIO CEO & Investor Digital Conference being held February 16-18, 2021.

The Company’s presentation will be made through the BIO CEO & Investor Digital Conference website and available on demand to registered participants during the conference at https://www.bio.org/events/bio-ceo-investor-digital-conference/company-presentations. Following the conference, the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com.

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL¹, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the second quarter of 2021² and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix’s lead vaccine candidate, TNX-1800³, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801³, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.

¹TNX-102 SL is an investigational new drug and has not been approved for any indication.

²Pending submission and agreement from FDA on statistical analysis plan.

³TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
Westwicke, an ICR Company
peter.vozzo@westwicke.com
(443) 213-0505

FAQ

What is the date of the BIO CEO & Investor Digital Conference for Tonix Pharmaceuticals?

The BIO CEO & Investor Digital Conference will take place from February 16-18, 2021.

Who represents Tonix Pharmaceuticals at the BIO CEO & Investor Digital Conference?

Seth Lederman, M.D., the President and CEO of Tonix Pharmaceuticals, will represent the company.

How can I access Tonix Pharmaceuticals' presentation from the conference?

The presentation will be available on demand via the BIO CEO & Investor Digital Conference website for registered participants.

What are Tonix Pharmaceuticals' leading product candidates?

Tonix's lead candidates include TNX-102 SL for fibromyalgia and TNX-1800, a vaccine candidate against COVID-19.

When is the expected interim data from the RALLY Phase 3 study?

The interim data from the RALLY Phase 3 study is expected in the second quarter of 2021.

What other diseases is Tonix Pharmaceuticals targeting with its products?

Tonix is also developing products for immunosuppression, cancer, and autoimmune diseases.